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Abstract
Background: Cancer related fatigue (CRF) is one of the most prevalent and distressing long-term complaints reported
by (non-) Hodgkin survivors. To date there has been no standard treatment for CRF in this population. A novel
and promising approach to treat CRF is exposure to bright white light therapy. Yet, large scale randomized
controlled trials testing its efficacy in these patients and research on potential mechanisms is lacking. The
objective of the current study is to investigate the efficacy of light therapy as a treatment for CRF and to explore
potential mechanisms.
Methods/design: In a multicenter, randomized controlled trial we are evaluating the efficacy of two intensities
of light therapy in reducing CRF complaints and restrictions caused by CRF in survivors of Hodgkin lymphoma
or diffuse large B-cell lymphoma. Secondary outcomes include sleep quality, depression, anxiety, quality of life,
cognitive complaints, cancer worries, fatigue catastrophizing, self-efficacy to handle fatigue, biological circadian
rhythms of melatonin, cortisol and activity, and biomarkers of inflammation. We will recruit 128 survivors, with
fatigue complaints, from academic and general hospitals. Survivors are randomized to either an intervention
(exposure to bright white light) or a comparison group (exposure to dim white light). The longitudinal design
includes four measurement points at baseline (T0), post-intervention at 3.5 weeks (T1), 3 months post-intervention (T2)
and 9 months post-intervention (T3). Each measurement point includes self-reported questionnaires and actigraphy
(10 days). T0 and T1 measurements also include collection of blood and saliva samples.
Discussion: Light therapy has the potential to be an effective treatment for CRF in cancer survivors. This study
will provide insights on its efficacy and potential mechanisms. If proven to be effective, light therapy will provide an
easy to deliver, low-cost and low-burden intervention, introducing a new era in the treatment of CRF.
Trial registration: The study is registered at ClinicalTrials.gov on August 8th 2017(NCT03242902).
Keywords: Cancer related fatigue, Light therapy, Sleep quality, Randomized controlled trial, Hematology,
Circadian rhythms
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Background
After the introduction of modern radiotherapy and com-
bination chemotherapy, Hodgkin lymphoma (HL) has
become the prototype of a curable malignancy with cure
rates of 80 to 90% [1]. Also, for selected patients with ag-
gressive non-Hodgkin lymphoma, survival has improved
significantly, i.e. the 5-year overall survival of patients with
diffuse large B-cell lymphoma (DLBCL) varies from 40 to
85% [2]. Unfortunately, treatment of lymphoma is associ-
ated with various late adverse effects, including cancer
related fatigue (CRF) [3].
CRF is defined as “a distressing, persistent, subjective
sense of physical, emotional, and/or cognitive tiredness or
exhaustion related to cancer and/or cancer treatment that
is not proportional to recent activity and interferes with
usual functioning” [4, 5]. Patients feel tired even after rest-
ing, have reduced capacity to carry out normal activities,
experience slow physical recovery from tasks, and report
diminished concentration [6]. CRF is one of the most fre-
quently reported long-term symptoms in (non-) Hodgkin
survivors with prevalence ratings between 25 to 60% com-
pared to 10 to 25% in the general population [7, 8]. CRF
significantly affects patients’ quality of life [5] and seems
to be influenced by symptoms of depression, anxiety, and
the presence of comorbid conditions [8].
Currently, there is no standard treatment for CRF. A
range of non-pharmacological interventions to treat CRF
have been investigated, including physical activity (PA),
psycho-education, cognitive-behavior therapy (CBT), CBT
with hypnosis (CBTH), mindfulness-based approaches, and
a number of complementary and alternative medicine
interventions (e.g., acupuncture/acupressure, yoga, music
therapy) [5]. Some of these interventions, including PA
[9, 10], CBT [11], and CBTH [12], have been associ-
ated with large effect sizes. In the case of CBT, these
effects remain stable for at least 2 years [13]. These
findings are promising but not without limitations.
For example, motivation is essential to complete these
interventions while fatigue can reduce the motivation
for PA [14]. Also, CBT is labor intensive since it re-
quires professional guidance for several weeks.
A new development in the treatment of CRF is the use
of light therapy. During this therapy, patients are asked to
expose themselves to bright white light (BWL) for 30 min
within the first half hour after awakening. Systematic ex-
posure to BWL was originally developed to treat seasonal
affective disorder [15] and is currently the treatment of
choice for this disorder [16–18] although a recent review
provided less conclusive results [19]. Additionally, light
therapy has been found to help restore circadian rhythm
disturbances and sleep disorders [20, 21].
Several studies have investigated the efficacy of light
therapy specifically for CRF. One study randomized breast
cancer patients undergoing chemotherapy to either a BWL
(n = 23) or a dim red light (DRL; n = 16) condition [22].
Results showed that the usual increase in CRF from base-
line to the end of the fourth chemotherapy cycle was seen
in women exposed to DRL, while such an increase was not
seen in the group exposed to BWL. In addition, circadian
rhythms became more synchronized and quality of life was
better in the women exposed to BWL compared to
women exposed to DRL. Another study used the same de-
sign to test the efficacy of light therapy for CRF in cancer
survivors [23]. Results showed that fatigue decreased to
normal levels in survivors exposed to BWL (n = 18) while
survivors exposed to DRL (n = 18) stayed at clinically
significant levels of fatigue. These results also showed a
significant decrease in depressive symptoms and better
sleep quality in survivors exposed to BWL compared to
DRL. More recently, results were published from a larger
RCT that included 81 cancer survivors [24]. Survivors ex-
posed to BWL showed greater reductions in fatigue
and improvements in mood, depressive symptoms and
quality of life compared to survivors exposed to DRL.
In summary, these findings support the use of light
therapy as a treatment for CRF.
However, the mechanisms that explain the effect of light
therapy on CRF have largely remained unexplored. Light is
one of the strongest synchronizers of the circadian rhythm
system [25]. When it enters the eye, light affects processes
in the suprachiasmatic nucleus (SCN), a structure better
known as the human master pacemaker of circadian
rhythms [26]. Based on this knowledge, several hypotheses
about potential mechanisms could be formulated.
The first hypothesis is that light therapy normalizes the
sleep-wake cycle. Previous studies showed that sleep-wake
cycles, measured with questionnaires as well as objective
measurements with actigraphy, were disrupted in patients
with cancer after chemotherapy and that this disruption
was related to increased CRF [22, 27]. Furthermore, it was
shown that light therapy during chemotherapy resulted in
sleep-wake cycles that returned to baseline levels after
chemotherapy while patients in the comparison condition
showed disrupted sleep-wake cycles after four cycles of
chemotherapy [27]. Moreover, secondary analysis on
objective sleep data collected with actigraphy in cancer sur-
vivors with CRF suggested that exposure to bright white
light improved the sleep efficiency to normal ranges while
this improvement was not seen in the group exposed to
dim red light [28].
The second hypothesis is that the mechanism may be
related to changes in circadian rhythms. The superchias-
matic nucleus (SCN) is responsible for the production of
melatonin, a hormone that is secreted in darkness, which
acts as a time-cue for sleep. Melatonin shows a circadian
rhythm with rising levels during the evening that reaches
the peak during the night followed by a decrease that
reaches its lowest point (nadir) in the morning. The SCN
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also plays a role in the production of cortisol, a
glucocorticoid hormone that shows a sharp increase in
the first 30 min after awakening, followed by a gradual
decline over the day that reaches its nadir during the
night [29]. Impairments of this rhythmicity, such as
the flattened morning-rise and a lower ratio between
morning and nocturnal levels of cortisol, have consist-
ently been associated with deteriorations in mood in
both healthy and clinical populations and increased
CRF in clinical populations [30–32]. Light therapy was
proven to be effective in entrainment of the circadian
rhythms of melatonin and cortisol [33]. Moreover,
improvements in CRF over time were associated with
normalization of the circadian cortisol rhythm [34],
suggesting that a potential mechanism of light therapy
on CRF is via the normalization of the circadian
rhythms of these hormones.
A third potential mechanism is the normalizing effect of
light therapy on the HPA axis, which may affect inflamma-
tory cytokine activity. There is a wealth of research, both in
animals as well as in clinical and healthy human popula-
tions, showing strong interconnections between fatigue and
inflammation. Consistent associations have been shown
between CRF and plasma levels of inflammatory markers
such as interleukin-6 and C-reactive protein [35, 36]. There
is also a well characterized feedback loop between the HPA
axis and inflammation, whereby the HPA axis can down
regulate inflammation and is itself up regulated by inflam-
matory signaling [37]. BWL has been found to normalize
HPA axis function [38] raising the possibility that BWL
may affect inflammatory cytokine activity either directly or
indirectly, e.g., via its normalizing effects on the HPA axis.
The main aim of this double-blind, randomized con-
trolled trial, called ‘improving Sleep quality, Psychosocial
functioning and cAncer Related fatigue with Light thErapy
(SPARKLE)’, is to determine the effect of exposure to BWL
compared to exposure to dim white light (DWL), on CRF
in ≥2 years survivors of HL and DLBCL. Additionally, this
trial will explore potential mechanisms of light therapy on
CRF by investigating the influence of light therapy on
factors associated with CRF. More specific, the secondary
objectives are:
1. to examine the effect of exposure to BWL compared
to DWL on sleep quality and psychological variables
(depression, anxiety, cognitive complaints, and quality
of life).
2. to investigate whether exposure to BWL, compared
to DWL, affects circadian rhythms of cortisol and
melatonin, activity, vitamin D concentrations and
levels of biomarkers for inflammation markers.
3. to explore whether the effects of exposure to BWL
on CRF can be predicted by the effect of BWL on
sleep quality, psychological variables, biological and
activity circadian rhythms, and inflammation
markers.
Methods
This trial will use a double blind randomized controlled
trial design with one intervention group exposed to
bright white light and one comparison group exposed
to dim white light. The design of the trial and the antic-
ipated flow is shown in Fig. 1. This trial (under number
NL61017.031.17) has been approved by The Institu-
tional Review Board of The Netherlands Cancer Insti-
tute as well as by the review boards of the participating
hospitals (see recruitment and randomization). Patient
recruitment and data collection started in August 2017.
Participants
The intended study sample will comprise 128 survivors of
Hodgkin lymphoma (HL) or diffuse large B-cell lymphoma
(DLBCL). Inclusion criteria are: (1) a survivorship of
≥2 years; (2) presence of moderate to severe fatigue symp-
toms since diagnosis of or treatment for HL or DLBCL.
The presence of fatigue will be defined by fulfilling at least
one of the following criteria: (a) a moderate to severe
fatigue score on the general fatigue subscale of the multidi-
mensional fatigue index; (b) a score of ≥17 on the Work
and Social Adjustment Scale indicating clinical levels of
impairments in daily functioning caused by fatigue [39].
Exclusion criteria are: (1) presence of somatic cause
for fatigue (defined as (a) New York Heart Association
class 3/4 (heart failure), (b) having a COPD gold class
3/4 (lung failure), or (c) having other organ failure that
has led to marked limitation of physical activity). Patient
can be included if, despite having used stable medication
for ≥6 months for the somatic cause, fatigue complaints
remain; (2) pregnancy (until 3 months postnatal) or lactat-
ing; (3) having had extensive surgery in the past 3 months;
(4) having a current diagnosis of psychiatric disorder that
can hamper participation; (5) having had a diagnosis of
and/or treatment for secondary malignancy in the past
12 months; (6) presence of photophobia or other eye
diseases that show symptoms of photophobia; (7) current
or previous use of light therapy (≥ 1 week); (8) current
employment in shift work.
Recruitment
Participants for this study will be recruited via collaborating
BETER-clinics. The BETER consortium (Better care after
Hodgkin lymphoma: Evaluation of long-Term Treatment
Effects and screening) is organising a nationwide infrastruc-
ture for survivorship care for lymphoma survivors, to pre-
vent morbidity and mortality from late treatment effects
[40]. This consortium identifies and traces 5-year survivors
of HL and DLBCL treated in 23 Dutch academic as well
as general hospitals. So far, eight BETER-clinics agreed
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to collaborate with the SPARKLE study: Antoni van
Leeuwenhoek, LUMC, Radboudumc, VUmc, UMCU,
ErasmusMC, Albert Schweitzer hospital, HagaZieken-
huis, Admiraal de Ruyter hospital.
Survivors (≥ 2 years) of HL or DLBCL who visit their
treating physician for follow-up care are screened for CRF
symptoms. When CRF symptoms are present and the pa-
tient meets the inclusion criteria, the physician will hand
out a pamphlet, a response card and a screening question-
naire to the patient. A second strategy to recruit patients
is via an evaluation of the BETER screening questionnaire
that patients complete for their first BETER-clinic visit.
This questionnaire includes a visual analogue scale (VAS)
scale from 0 (no fatigue) to 10 (worst imaginable fatigue).
If the fatigue score is 4 or higher, patients will be sent the
information package.
Patients are asked to return the response card to express
their interest in participation. In case of no interest, patients
are asked to specify their reason(s) on the response card. If
patients are interested, they are asked to complete the
screening questionnaire and return this to the SPARKLE
research team. Non-responders will receive a reminder 3
weeks after receiving the information package.
Patients who return the screening questionnaire receive
a call from the SPARKLE research team. The aim of this
phone call is to provide more information about the study
and to screen on inclusion and exclusion criteria. Interested
and eligible patients will receive a more detailed patient in-
formation letter and an informed consent form. Patients
are requested to return a signed informed consent or a
no-interest-response-card within 2 weeks. Non-responders
will be called to assess willingness for participation 3 weeks
after sending the patient information letter.
Randomization
Equally distributed across all four seasons, participants are
randomized to either an intervention group (n = 64) or a
comparison condition (n = 64) using the minimization
technique at a 1:1 ratio. Randomization is stratified for
diagnosis (HL; DLBCL), time since diagnosis (< 5 years;
5–10 years; 11–20 years; > 20 years) and gender (male; fe-
male). Randomization is outsourced to an independent
party, using the randomization programme ALEA. The
output determines which lamp (with BWL or with DWL)
is offered to each participant. This lamp will be part of the
content of a bag offered to the research assistant who
visits the participants. In this way, both the research team
and the participants are blinded to the allocated condition.
The randomization code will only be broken if a patient
Fig. 1 Overview of the trial design
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reports severe adverse side effects as a result of the light
intervention.
Description of interventions
Instructions for light therapy are equal in both conditions.
All participants self-administer light therapy at home for
30 min each morning during a period of 3,5 weeks.
Participants start with the light therapy within 30 min after
waking up and position the light box at a distance of 45 cm
and an angle of 45° from their face. During the light therapy
participants can engage in other activities such as reading
or having breakfast. They are informed not to stare into the
light but to keep their eyes open to ensure that light falls on
the retina. No instructions for sleep pattern adjustments
are provided in the current trial.
Light therapy in both conditions will be administered via a
Litebook© Edge (Litebook, Ltc. Medicine Hat, Canada). The
Litebook© Edge is a small (15 × 12 × 1 cm), lightweight box
designed to be placed on a table. The Litebook© Edge con-
tains 60 premium white light emitting diode (LED) lights
which mimic the visible spectrum of sunlight for minimum
glare and maximum eye comfort. For purposes of safety, the
Litebook© Edge emits no ultraviolet light. The Litebook©
Edge devices used in this study were modified to include an
integrated meter that allows for adherence monitoring by
recording time and duration of on-time on each day.
Intervention group
The intervention group will be exposed to BWL with an
intensity of 10.000 lx at a distance of 45 cm. The spectrum
of the light in this condition will be enriched around
480 nm wavelengths. Light with this colour has previously
been shown to be the effective factor in light therapy as it
is associated with melatonin suppression [26].
Comparison group
Participants in the comparison condition will be exposed to
dim white light, with an intensity of 10–20 lx at a distance
of 45 cm. This light was successfully used as a comparison
condition for BWL therapy in Alzheimer’s disease. Similar
results are expected in cancer survivors [personal commu-
nication with Dr. M.G. Figueiro, November 14, 2016].
Study procedure
All participants complete a battery of self-report question-
naires and wear a wrist actigraph at four different measure-
ment points (T0: baseline; T1: directly after 3,5 weeks of
light therapy; T2: 3 months after light therapy; T3: 9 months
after light therapy). The first (T0) and second (T1) meas-
urement points include a visit to the hospital to provide
participants with materials and instructions, to perform
cognitive tests, and to collect blood (during the visit) and
saliva (on day 8 and 36) samples. Figure 2 shows a sche-
matic diagram of a participant’s timeline.
The research assistant or study coordinator calls the
participant after 5 days of light therapy asking for the
occurrence of any side effects (headache, nausea, agi-
tated feeling and irritated eyes). In normal cases, these
side effects vanish in a few days. Light therapy is termi-
nated when these side effects are still present after
5 days of light therapy. These participants are asked to
complete all follow-up assessments.
Fig. 2 Overview of study procedure
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After 3,5 weeks of light therapy, participants are asked
not to use light therapy during the follow-up measure-
ments. No instructions are provided for the use of con-
comitant care and other interventions.
Study measures
Sociodemographic and clinical data
Information regarding the patients’ age, education, marital
status, living situation, work status and medication use will
be obtained via a questionnaire. Clinical information, in-
cluding date of diagnosis, tumor characteristics, and treat-
ment history will be abstracted from the BETER-database.
This clinical information will be abstracted from the pa-
tients’ medical record when participants are not included in
the BETER-consortium. Current season will be derived
from the start date of light therapy.
Outcome measures
The Multidimensional Fatigue Inventory (MFI) [41], a
VAS-scale for fatigue [42] and the Work and Social Adjust-
ment Scale (WSAS) [43] are the primary outcome measure
of this study. Secondary outcome measures include: Pitts-
burg Sleep Quality Index (PSQI) [44], wrist actigraphy [45],
Center for Epidemiological Studies – Depression scale
(CES-D) [46], State-Trait Anxiety Inventory-6 items
(STAI-6) [47], Medical outcome studies short form
(SF-36) [48], Medical Outcomes Studies Cognitive
function scale (MOS-CF6) [49], MD Anderson Symp-
tom Inventory (MDASI) [50], Psychomotor Vigilance
Task (PVT) [51], 15 words task [52], digit span task [53],
cancer worry scale (CWS) [54], fatigue catastrophizing
scale (FCS) [55], Self-efficacy scale 28 (SES-28) [56],
salivary cortisol and melatonin, and inflammatory bio-
markers. Detailed descriptions of these outcome measures
are provided in Table 1.
A brief self-developed questionnaire will be used to
examine the use of alcohol and caffeine, screen time prior
to sleeping, solarium, wake-up lights, or the use of other in-
terventions that could impact CRF (including physical exer-
cise, CBT, or other interventions). Additional questions
assess participant’s experience, compliance, and satisfaction
with light therapy. Compliance is also assessed with a light
therapy log during light therapy.
Actigraphy
Objective measures of sleep and circadian activity will
be monitored with an accelerometer in a microelectro-
mechanical system (MotionWatch8, Camntech, Cam-
bridgeshire, United Kingdom). The MotionWatch8 is a
small device, similar in size to a watch, with a tri-axial
accelerometer. It has a 4.0 Mbits storage capacity and a
waterproof casing. This watch will be worn on the
non-dominant wrist for 10 (24-h) days at all measure-
ment points and during light therapy. Output of the
MotionWatch8 includes the following sleep parameters:
time in bed, time out of bed, sleep onset latency (min),
sleep efficiency, total time in bed (min), total sleep time
(min), wake after sleep onset (min), number of awaken-
ings, and average awakening time (min). Additionally,
output of the MotionWatch8 includes the following cir-
cadian activity rhythm variables: interdaily stability (IS),
Intra-Daily Variability (IV), Least 5 (L5) average, Most
10 (M10) average, and relative amplitude (RA). In
addition, it offers nap analyses for naps during the day
and day activity analyses.
An actigraphy log will be used to ensure that the scor-
ing software of the actigraph detects the sleep habits of
participants accurately. Based on the guidelines for the
use of actigraphy, the following items will be included:
bed time, attempted time to fall asleep, wake-up time,
out-of-bed time, time of day time naps, times the acti-
graph was removed, unusual circumstances that might
have affected sleep/wake patterns (such as illness) [45].
Biological samples
Salivary cortisol All participants will be asked to collect
saliva to assess cortisol on five different time points dur-
ing 24 consecutive hours: 1) at personal waking time, 2)
30 min after awakening, 3) 45 min after awakening, 4) at
16.00 o’clock, and 5) at bedtime. These time points are
chosen in line with published guidelines for determin-
ation of the Cortisol Awakening Response (CAR) [57].
The afternoon and evening samples are used to estimate
the diurnal cortisol slope and the area under the curve.
Saliva will be collected by a passive drool technique
into a propylene vial. Participants are not allowed to
smoke, engage in vigorous exercise, eat or drink caffein-
ated drinks or food, and eat protein-rich meal during
the sampling period starting 1 h prior to sampling.
Eating and drinking of other nourishments is allowed
until 5 min prior to sampling. Brushing of teeth is not
allowed for 30 min before sampling. After sampling, the
participant is instructed to record the time that they
completed the sample and to refrigerate it. Samples will be
returned to the study coordinator by mail after which the
samples will be frozen at − 80 °C to keep samples stable
until analysis. Cortisol levels will be determined with an
electrochemiluminescensce immunoassay ‘ECLIA’ on the
Cobas®6000 analyzer (Roche Diagnostics GmbH, Mann-
heim, Germany).
Salivary melatonin A subgroup (n = 25 per condition)
will be asked to collect five additional saliva samples in
the evening to determine the Dim Light Melatonin Onset
(DLMO). Starting point for this saliva collection will be
5 h prior to usual bedtime followed by one sample every
sequential hour. Previous research indicated that these
time points provide a reliable measurement for DLMO
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with at home collected saliva samples [58]. Participants
receive the additional instruction to collect these sam-
ples in dim light conditions.
A commercial direct saliva melatonin radioimmunoassay
(RIA; Bühlmann laboratories, Schönenbuch, Switzerland)
will be used to assess melatonin levels in saliva. The
DLMO will be determined based on a threshold of 4.0 pg/
mL. Previous research indicated that a fixed thresh-
old is the most convenient way to determine DLMO
although there is a risk that DLMO cannot be
determined in patients with sleep problems as a con-
sequence of low secretion of melatonin [58]. When
we address this problem in the current study, an al-
ternative procedure will be used. DLMO will then be
defined as the time when melatonin concentration is
two SD above the basal mean of three daytime
samples [59].
Blood samples Blood samples are collected to measure
biomarkers of inflammation and vitamin D at baseline.
Table 1 Study outcome measures and corresponding questionnaires
Variable Questionnaire Number/type of items Time frame Score range Psychometric details
Primary outcomes
Cancer related
fatigue
MFI [41] 20
four-point Likert scale
Past few days Subscale scores: 4–20; higher
scores indicate more fatigue
Subscales: general fatigue, mental
fatigue, physical fatigue, reduced
motivation, reduced activity.
Cronbach’s alpha: 0.84
VAS-scale [42] 1
eleven-point Likert scale
This moment 0–10; higher scores indicate
more fatigue
Restrictions
caused by
fatigue
WSAS [43, 70] 5
nine-point Likert scale
Influence of
fatigue on
daily life
0–40; higher scores indicate
higher levels of disability
Cronbach’s alpha: > 0 .79
Secondary outcomes
Sleep quality PSQI [44] 19
four-point Likert scale and
open-ended questions
Past month Total score: 0–21
Subscale scores: 0–3; higher
scores indicate more acute
sleep disturbances
Subscales: subjective sleep quality,
sleep latency, sleep duration,
habitual sleep efficiency, sleep
disturbances, use of sleeping
medication, daytime dysfunction.
Cronbach’s alpha: 0.83
Depression CES-D [46, 71] 20
four-point Likert scale
Past week 0–60; higher scores indicate
greater depressive symptoms
Cronbach’s alpha: 0.85–0.90
Anxiety STAI-6 [47] 6
four-point Likert scale
This moment 20–80; higher scores indicate
increased anxiety
Cronbach’s alpha: 0.83
Quality of life SF-36 [48, 72] 36
Dichotomous
three to six-point Likert scale
Past 4 weeks Subscale scores: 0–100; higher
scores indicates higher levels
of functioning/well-being
Subscales: physical functioning,
role limitations due to physical
health problems, bodily pain,
social functioning, general mental
health, role limitations due to
emotional problems, vitality,
general health perceptions
Cronbach’s alpha: 0.84
Cognitive
complaints
MOS-CF6 [49, 73] 6
six-point Likert scale
Past week 0–100; higher scores indicated
better cognitive functioning
Cronbach’s alpha: ≥ 0.89
MDASI [50] 8
eleven-point Likert scale
Past 24 h 0–80; higher score indicates
worse or more disturbing
cognitive complaints
Cancer worries CWS [54] 8 + 1
four-point Likert scale
Past week 9–36; higher score indicates
more frequent worries about
cancer
Cronbach’s alpha: 0.87
Fatigue
catastrophizing
FCS [55, 74] 10
five-point Likert scale
Current
attitude
10–40; higher score indicates
more catastrophizing
Cronbach’s alpha: 0.85
Self-efficacy SES-28 [56, 75] 7
four-point Likert scale
Current
attitude
7–28; higher score indicates
higher level of perceived
control over fatigue
symptoms
Cronbach’s alpha: 0.68–0.77
CES-D Center for Epidemiological Studies – Depression scale, CWS Cancer Worry Scale, FCS Fatigue catastrophizing Scale, MDASI MD Anderson Symptom Inventory,
MFI Multidimensional Fatigue Inventory, MOS-CF6 Medical Outcomes Studies Cognitive functioning, PSQI Pittsburgh Sleep Quality Index, SF-36 Medical Outcome
Studies short form, SES-28 Self-efficacy Scale 28, STAI-6 State Trait Anxiety Inventory-6 items, VAS Visual Analogue Scale, WSAS Work and Social Adjustment Scale
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During T0 and T1, two tubes of 10 mL of blood will be
collected. One of these tubes will be saved in the bio-
bank NKI-AVL. The other will be used to assess vitamin
D and the following inflammatory biomarkers in dupli-
cate by ELISA: IL-1RA, hsIL-6, sTNF-RII, and hsCRP.
Vitamin D has been associated with current levels of fa-
tigue [60–62]. The before-mentioned biomarkers have
previously been associated with fatigue in patients with
cancer [35, 63]. The level of these biomarkers, as well as
the change in biomarker levels will be used as parame-
ters for the statistical analysis.
Data management
The original signed informed consent forms are stored at
the department of the participating institute where the par-
ticipant is recruited. All participants receive a unique par-
ticipant number, in order to code their outcome measures
without the risk of harming anonymity. Participants can
choose to complete an online or pen-and-paper version of
the questionnaire. Paper versions of completed question-
naires and a (copy of) the signed informed consent forms
are stored at the Division of Psychosocial Research and Epi-
demiology of the Netherlands Cancer Institute separately.
Online completion of questionnaires will take place via an
online secured (HTTPS) research tool, called Explora Zorg,
which is specifically developed for research in Dutch health
care. Each participant has a personal log-in code. Com-
pleted paper versions of the questionnaires will be entered
in this online system by the research assistant.
The information given online by patients is accessible to
the study staff only, via a secured code. This code is known
by the principal investigator (EB), the study coordinator
(DS), and the research assistant (JG). The principal investi-
gator will safeguard the key to the code. The collected data
in this research tool is saved on the secured database of the
Netherlands Cancer Institute on a monthly basis.
Blood and saliva samples of all participants are stored at
the general clinical laboratory of the Netherlands Cancer In-
stitute. Each sample is coded with a unique participant num-
ber. Date and time of sampling are reported on the samples.
Statistical methods
Sample size calculation
The MFI is the primary outcome on which sample size cal-
culations are based. With a sample of 128 patients (n = 64
per group), the study will have an 80% power to detect an
Cohen’s effect size of 0.5 for the main effect of light therapy
on fatigue with a p-value set at 0.05 (power calculation with
G*power 3 [64]). Cohen’s effect size of 0.5 means a 0.5
standard deviation difference on the primary measurement
outcome, which is considered to be a clinical meaning-
ful difference [65]. Participants who discontinue light
therapy but complete questionnaires will be included in
the intention-to-treat analysis.
Statistical analyses
Data will be analysed using the Statistical Package for the
Social Sciences (SPSS). Although we endeavour to check
all questionnaires upon their return and call participants
to complete missing items, some data might still be miss-
ing. Missing values will be imputed according to the man-
ual of the questionnaire. In general, descriptive statistics
will be computed for the outcome variables, potential co-
variates and demographic variables. Bivariate analyses will
be undertaken to explore associations between outcome
and potentially confounding variables (e.g. season, diagno-
sis, years since diagnosis) using correlations (for continuous
variables) and Chi-square tests (for categorical variables).
Group differences in change in fatigue during the trial
will be investigated using a mixed effect growth model with
random intercept and slope, nested within site (clusters of
different hospitals). This approach takes into account the
within and between person variability, and deals adequately
with missing data [66]. If baseline differences are identified
despite randomisation, these variables will be accounted for
in the model. In case of non-ignorable dropout we will cor-
rect the model for different patterns of missing values [67].
All analyses will be done on an ´intention to treat´ basis.
Additional explorative analyses will be done on a ´per
protocol´ basis.
The mixed effect model approach described for change
in fatigue will also be used to determine treatment effects
of continuous secondary outcome measures. To evaluate
between-group differences in categorical secondary out-
come measures, we will use generalized estimating equa-
tions (GEE) for longitudinal data. This approach accounts
for correlated within subject responses, allows for not
normally distributed variables and deals adequately with
missing data [67–69]. Since there are multiple outcomes,
the p-values for each model will be adjusted for multiple
comparisons.
Within the intervention group we will explore
which variables are predictive for the efficacy of light
therapy in reducing fatigue. A mixed effect model for
longitudinal data will be used with fatigue as dependent
variable and the following independent variables: sleep
quality, depression, anxiety, cognitive complaints, quality
of life, and biological circadian rhythms. The p-values will
be adjusted for multiple testing.
Monitoring
The Institutional Review Board of The Netherlands
Cancer Institute did not appoint a data monitoring
committee because of the low risk on adverse events.
Instead, the investigator submits a summary of the
progress of the trial to the accredited METC once a
year. Information is provided on the date of inclusion
of the first subject, numbers of subjects included and
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numbers of subjects that have completed the trial, ser-
ious adverse events/ serious adverse reactions, other
problems, and amendments. Some study sites require
adherence to local monitoring protocols.
Discussion
CRF affects approximately 40 to 60% of long-term survi-
vors treated for (non-) Hodgkin lymphoma. Recently,
interest shifted to light therapy as a promising treatment
for CRF. Previous studies showed a prevention of in-
creasing levels of CRF in breast cancer patients during
chemotherapy and a reduction of fatigue complaints in
cancer survivors after exposure to BWL compared to ex-
posure to dim red light. Yet, the patient samples in these
studies were small and knowledge of possible mecha-
nisms and long-term effect of light therapy is lacking.
This trial investigates the efficacy of light therapy in sur-
vivors of HL and DLBCL and explores potential mecha-
nisms explaining its efficacy, including chronobiological
and psychosocial pathways.
This trial has several noteworthy strengths, including (1)
the randomized controlled trial design; (2) recruitment in
multiple centers across the Netherlands; (3) the use of a
dim white light comparison condition instead of a dim red
light comparison condition to exclude the influence of
light color; (4) the use of intention-to-treat analyses; and
(5) inclusion of long-term follow-up measurements to
investigate the long-term efficacy of light therapy.
There are also several limitations in this trial. First, for
practical reasons the duration of light therapy is 3,5 weeks
in the current study while previous studies provided light
therapy for 4 weeks. Since light therapy for CRF is an up-
coming research field, the duration of light therapy and its
efficacy is not yet investigated. Clinical practice suggests
that the effect of light therapy is often seen within 2
weeks. If no effect is seen in this period, than it is unlikely
to see a change in the following weeks. For this reason, it
is expected that shortening the time period of light ther-
apy with 4 days will not impact the efficacy of light ther-
apy. Second, a somatic cause for fatigue complaints is an
exclusion criterion. Yet, screening does not include assess-
ments of possible somatic factors. Instead, the treating
physician judges whether a patient has a somatic cause for
fatigue or not. In case of doubt, a team of three experts
will be consulted to judge whether someone can be in-
cluded in the trial. Third, the DLMO is assessed with 5
saliva collections starting 5 h prior to sleep onset. Recom-
mendations by EUCLOCK (a large European wide re-
search network aiming to investigate the circadian clock
in single cells and humans) advices to include a saliva col-
lection until 1 h after sleep onset. Yet, this would influ-
ence someone’s sleep pattern and might affect fatigue
levels the following day. For this reason, saliva is only
collected prior to sleep onset.
In conclusion, new insights suggest the efficacy of light
therapy as a treatment for cancer related fatigue. If
proven to be effective, light therapy will provide an easy
to deliver, low-cost and low-burden intervention, intro-
ducing a new era in the treatment of CRF. National im-
plementation of light therapy will be facilitated via close
collaboration with the BETER-clinics. Moreover, the in-
vestigation of potential mechanisms enriches the CRF
literature with possible new suggestions for causative
factors of CRF, a symptom that is neither well under-
stood nor treated.
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